Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities
Net loss	$ (23,290,661)	$ (15,686,494)
Adjustments to reconcile net loss to cash used in operating activities:
Stock compensation expense	4,277,263	879,375
Depreciation and amortization	48,721	99,075
Amortization of debt discount		1,107,009
Loss on share settlement of Kineta employee compensation assumed from merger	185,019
Change in fair value of derivative liability		313,772
Change in fair value of Kineta merger holdback shares	315,660
Changes in operating assets and liabilities
Other current assets	333,077	69,704
Other noncurrent assets	(30,576)	(153,283)
Accounts payable and accrued expenses	(3,911,631)	1,242,321
Net cash flows from operating activities	(22,073,128)	(12,128,521)
Cash flows from investing activities:
Cash paid for business acquisition, net of cash received from Kineta	(1,259,278)	(5,192,371)
Purchase of property and equipment	(48,233)	(36,498)
Net cash flows from investing activities	(1,307,511)	(5,228,869)
Cash flows from financing activities:
Cash dividend payment of preferred stock Series A	(6,267)
Proceeds from warrants exercised	3,620,657	1,931,004
Proceeds from convertible notes payable		28,568,000
Payment of debt issuance costs		(1,112,362)
Proceeds from issuance of common stock	12,112,172	5,000,000
Proceeds from stock options exercised		104,000
Payment of debt assumed from Kineta merger	(434,000)
Payment of note payables to former Kineta employees	(98,677)
Payment of transaction costs related to Kintara merger	(500,000)
Principal payments of finance lease	(43,671)
Payment of placement agent fees and offering costs	(679,337)	(1,202,262)
Payment of net liabilities assumed in reverse recapitalization with Kintara	(550,000)
Net cash flows from financing activities	13,420,877	33,288,380
Net change in cash and cash equivalents	(9,959,762)	15,930,990
Cash and cash equivalents at the beginning of the period	12,657,178	3,665,032
Cash and cash equivalents at the end of the period	2,697,416	19,596,022
Supplemental disclosure of cash flow information
Cash paid for interest	16,533
Supplemental non-cash activity
Kineta employee compensation assumed from merger exchanged for note payables	592,063
Consideration in common shares for Kineta acquisition	8,915,661
Fair value of placement agent warrants issued in connection with common stock issuance	370,403
Fair value of investor warrants issued in connection with common stock issuance	9,259,821
Property and equipment recognized in exchange for finance lease obligations	172,453
Deferred offering costs not yet paid	$ 197,566	385,820
Right-of-use asset recognized in exchange for operating lease obligations		318,722
Debt issuance costs not yet paid		5,135
Fair value of warrants associated with convertible notes payable		6,520,056
Derivative liability associated with make-whole premium		2,402,228
Deemed dividend on warrant modifications		965,177
Issuance of common stock for placement agent fees		$ 443,560

TuHURA Biosciences, Inc./NV 10-Q